Eton Pharmaceuticals Stock Price, News & Analysis

Eton Pharmaceuticals announced the sale of its neurology portfolio to Azurity Pharmaceuticals for up to $45 million, plus royalties on sales. The portfolio includes drug candidates ET-105, ET-104, and ET-101, which are under FDA review. CEO Sean Brynjelsen highlighted that this deal allows Eton to concentrate on its orphan drug business and improve profitability by avoiding sales force investments. Eton will receive $15 million at closing, with additional payments tied to regulatory and sales milestones.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) has announced the acquisition of Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc. This product is crucial for treating Adrenocortical Insufficiency in children under 17. Following its positive reception in the U.S., Eton aims to expand into the Canadian market, addressing significant unmet needs among pediatric patients. The acquisition reflects Eton's commitment to becoming a leader in orphan drug development, as noted by both Eton and Diurnal executives.

Eton Pharmaceuticals has received FDA acceptance for its new drug application (NDA) for topiramate oral solution, targeting pediatric and adolescent patients. The application, which includes three indications for seizures and migraine prevention, has a PDUFA date of August 6, 2021. This marks a significant step for Eton, which has three neurology-focused oral liquid products submitted to the FDA, all slated for approval in 2021. The company currently has three FDA-approved products and aims to develop treatments for rare pediatric diseases.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announces the exclusive availability of ALKINDI® SPRINKLE through AnovoRx Specialty Pharmacy. This FDA-approved treatment is designed for pediatric patients with Adrenocortical Insufficiency (AI), and provides dosing flexibility with strengths of 0.5 mg to 5 mg. The Eton Cares Program will assist patients in accessing this medication. Eton estimates that AI affects between 5,000 and 11,000 children in the U.S.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) reported Q3 2020 financial results, revealing a revenue of ($0.2) million, attributed to a price reduction of Biorphen. SG&A expenses rose to $3.4 million, while R&D expenses decreased to $2.8 million. The net loss increased to $6.5 million compared to $5.0 million a year ago. Eton successfully closed an oversubscribed equity offering raising approximately $22.5 million. Key milestones include the FDA approval of ALKINDI SPRINKLE, expected to launch by November, and four NDAs submitted with upcoming PDUFA dates in 2021.

Eton Pharmaceuticals (ETON) announced it will release its third quarter 2020 financial and operational results on November 12, 2020. A conference call to discuss these results and provide a business update is scheduled for 4:30 p.m. ET. The call can be accessed domestically at 1-866-795-8473 and internationally at 1-470-495-9161. Eton specializes in innovative treatments for rare pediatric diseases and has three FDA-approved products, with six additional products in late-stage development, five of which are submitted to the FDA.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) has successfully closed an offering of 3,220,000 shares of common stock at $7.00 per share, raising approximately $22.5 million before expenses. This total includes 420,000 shares from the underwriter's overallotment option. The net proceeds are earmarked for general corporate purposes such as research and development, capital expenditures, and working capital needs. National Securities Corporation managed the offering. Please refer to the SEC for the final prospectus details.

Eton Pharmaceuticals (Nasdaq: ETON) announced that the FDA has accepted its new drug application for zonisamide oral suspension, targeting partial seizures in epilepsy patients. The application has a PDUFA date set for May 29, 2021. This marks a significant step for Eton as zonisamide is one of three neurology-focused liquid products they expect to launch in 2021. Eton currently has three FDA-approved products and six in late-stage development, reflecting its commitment to innovating treatments for rare pediatric diseases.

Eton Pharmaceuticals, Inc (Nasdaq: ETON) announced the pricing of an underwritten public offering of 2,800,000 shares at $7.00 per share, totaling gross proceeds of $19.6 million. An additional 420,000 shares may be purchased by underwriters, potentially increasing proceeds to $22.5 million. The offering is set to close on or about October 16, 2020. Proceeds will be used for corporate purposes, including R&D and working capital. National Securities Corporation acts as the book-running manager. The shares are offered under an SEC registration statement.